Nanodroplet oxyGen delivery (NanO2) for ST-elevation myocardial InfarCtion: GNOSTIC
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Perflenapent (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms GNOSTIC
- 25 Mar 2025 New trial record
- 04 Mar 2025 According to a NuvOx Pharma media release, Successful completion of the GNOSTIC Trial may lead to a new paradigm in cardioprotection in acute heart attack to improve outcomes in this deadly disease.
- 04 Mar 2025 According to a NuvOx Pharma media release, Dr. Linda Peterson, Professor of Medicine and of Radiology at Washington University School of Medicine in St Louis, is Principal Investigator of the GNOSTIC Trial. T